Quality improvement and substance abuse: rethinking impaired provider policies.

Substance abuse is known to be our nation's number one public health problem. Physicians and other health providers can develop chemical dependency problems that create significant quality assurance and risk management dilemmas. Not all of society understands drug dependence to be a treatable medical disease and behavioral problem. Sometimes impaired providers are ignored or punished rather than treated and rehabilitated. This results in an enormous waste of human and monetary resources. In the last 10 years, impaired physician programs have developed focus and credibility. But certain difficulties exist in these programs: namely, that such programs are affected by tensions between medical societies and state licensing boards; that substance-dependent providers escape detection by moving to other states; that existing impaired provider programs have limited practical application within the federal health care system; and that liability risks are incurred if institutions rely on impaired provider policies that do not include all members of the medical staff. Hence, we argue that existing impaired provider policies might be worth rethinking. To promote that dialogue, we offer a sample policy for consideration and review. It includes specific actions and procedures for the identification, referral, and reentry of impaired providers and allows for National Practitioner Data Bank reporting in that process. The Data Bank has been in place for only a few years and offers society and the health community a new opportunity to better control chemically dependent, licensed medical staff without dismantling existing impaired provider programs. The policies for managing chemically dependent health professionals are changing from a focus on stigma and prosecution to one of early identification, rehabilitation, and reentry. We hope to advance that process.

A reevaluation of the association between instrument delivery and epidural analgesia.

BACKGROUND AND OBJECTIVES: Over 100 papers in the medical literature suggest pro or con that epidural analgesia is associated with an increase in the incidence of instrument delivery. This two-component study was performed to evaluate the influence of epidural labor analgesia on the incidence of instrument delivery. METHODS: Component 1 was a retrospective analysis of the medical records of 14,804 mothers having a vaginal delivery before and after implementation of an active epidural service. Component 2 was a case control study designed to determine factors, in addition to epidural analgesia, associated with an increase in instrument delivery. In component 2 11 factors describing maternal, fetal, anesthetic, and obstetric factors were analyzed for each of 609 consecutive patients having an instrument delivery and 246 controls having a spontaneous vaginal delivery. RESULTS: In component 1, despite a tenfold increase in the use of epidural analgesia, there was a similar association between epidural use and instrument delivery in both time periods. Additionally, the epidural-forceps association was twice as strong for parous patients as for nulliparous patients (odds-ratios 9.74 and 4.52, respectively). In component 2, five factors were significantly (P > .0001) associated with instrument delivery conclusions. CONCLUSIONS: While epidural analgesia was one factor, the others were gestational age > 41 weeks, a second stage of labor > 2 hours, an occiput posterior or transverse fetal position, and previous cesarean section. These four factors are individually and independently associated with an increase in the incidence of instrument delivery independent of epidural use.

Post-caesarean section analgesia: a comparison of epidural butorphanol and morphine.

Epidural butorphanol 1, 2 and 4 mg were compared with morphine, 5 mg, for postoperative analgesia in 92 consenting, healthy, term parturients who had undergone Caesarean section under epidural lidocaine anaesthesia in a randomized double-blind study. Postoperative pain was assessed using a visual analogue scale and recorded with heart rate, blood pressure and respiratory rate. The demographic characteristics, and the incidences of primary and repeat Caesarean sections, were not different among the four treatment groups. At 15, 30, 45 and 60 min after treatment the median pain scores following butorphanol were similar and lower than those following morphine (P less than 0.05). Calculated median percentage pain relief values for butorphanol were higher than morphine at each of these times (P less than 0.05). At 90 min and 2 hr the pain scores and pain relief values were similar. Beyond 45 min the number of patients requesting supplemental medication and dropping out of the study increased progressively in both the butorphanol and morphine treated patients. The attrition profiles for butorphanol were different from morphine (P less than 0.01). The median time in the study was greater than 24 hr for morphine, and 3, 2.5 and 4 hr for butorphanol, 1, 2 or 4 mg, respectively. No patient developed a clinically important change in heart rate or blood pressure, and none experienced a decrease in respiratory rate below 12 breaths.min-1. One of 69 patients (1.4 per cent) who received butorphanol developed pruritus compared with ten (43 per cent) of 23 patients who received morphine. The global assessments of the adequacy of analgesia were indistinguishable between morphine and butorphanol. Epidural butorphanol provides safe, effective postoperative analgesia, has a prompt onset, and a limited duration.

Vecuronium for rapid-sequence intubation for cesarean section.

Because succinylcholine may occasionally be contraindicated for rapid-sequence induction in parturients, we studied the use of vecuronium in 21 patients having elective cesarean sections. Eleven patients (group 1) received 10 micrograms/kg vecuronium as a priming dose, followed 4-6 min later by 100 micrograms/kg. Ten patients (group 2) received 200 micrograms/kg vecuronium as a bolus. Onset, the time from the injection of vecuronium to maximal twitch suppression, and clinical duration, the time between vecuronium administration and return to 25% of the control twitch height, were recorded. Umbilical and maternal venous blood samples at delivery were analyzed for vecuronium concentrations. One-minute and 5-min Apgar scores and 1- and 24-h Neurologic and Adaptive Capacity Scores (NACS) were recorded. Individual tests of passive and active tone within the overall NACS profile were compared to evaluate further any residual vecuronium effects in the infants. Onset of neuromuscular blockade was 177 s in group 1 and 175 s in group 2. The corresponding clinical durations were 73 and 115 min. Maternal and umbilical venous vecuronium concentrations were 515 and 73 ng/mL in group 1 and 838 and 107 ng/mL in group 2. Seventy percent of neonates in group 1 had Apgar scores greater than 7 at 1 min, with 100% greater than 7 at 5 min. Corresponding values in group 2 infants were 50% and 80%. Fifty percent of group 1 infants had NACS of 35-40 at 1 h, and 70% at 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Determination of hydralazine in human plasma by high-performance liquid chromatography with electrochemical detection.

Hydralazine is used as an antihypertensive vasodilator drug. A specific and sensitive method for extraction and analysis of hydralazine by high-performance liquid chromatography (HPLC) with electrochemical detection was developed. Hydralazine and 4-methylhydralazine (internal standard) in plasma were derivatized at room temperature with salicylaldehyde. The derivatives were extracted in basic medium with a mixture of heptane, methylene chloride and isopentyl alcohol. A very good separation of hydralazine and 4-methylhydralazine from matrix material was achieved on a Supelcosil LC-18-DB (5 microns) reversed-phase column kept at 28 degrees C with a mobile phase of 66% methanol in 0.055 M citric acid/0.02 M dibasic sodium phosphate (pH 2.5). The hydralazine level was measured electrochemically by a screen oxidation mode. This method offers significant advantages in sensitivity, specificity and accuracy. Sample analysis by HPLC required less than 8 min. Application of the method to monitor plasma levels of hydralazine from a patient receiving the drug for the treatment of severe pregnancy-induced hypertension is discussed.

Malignant hyperthermia and ECT.

The malignant hyperthermia syndrome is a rare hypermetabolic state that occurs in patients after the administration of certain drugs, most frequently anesthetics and/or succinylcholine. In view of the widespread use of succinylcholine to induce muscle relaxation prior to ECT, it is important that the individual who administers succinylcholine in this setting be familiar with the syndrome and its treatment. This report reviews what is known about malignant hyperthermia and proposes a course of action when the syndrome occurs in a patient undergoing ECT or a patient with known susceptibility to malignant hyperthermia needs ECT.

Unusual complication of Swan-Ganz catheter requiring mediastinotomy.

We were consulted to assist in the removal of an anchored Swan-Ganz catheter. After failing in several attempts to remove the catheter, we elected to return the patient to the operating room in the event that the catheter had been sutured to the right atrium. No evidence of this was found. We believe the catheter was anchored to the pulmonary bed, but the definite cause of this problem is still obscure.

Laboratory evaluation of pressure transducer domes containing a diaphragm.

Pressure transducers are being used with increasing frequency in patient care. The recent availability of sterile transducer domes containing a diaphragm provides a means for reducing the risk of bacteremia when using these devices. The present studies measured the effect of diaphragm domes on the accuracy of pressure measurement. The sensitivity and frequency responses of 5 pressure transducers utilizing diaphragm and nondiaphragm domes were compared. The results indicate that the type of dome utilized and the method of dome application can significantly modify pressure transducer performance. The data are useful in providing optimal accuracy and reliability of pressure measurments when using a diaphragm dome, pressure transducer combination.

Antiarrhythmic anesthetic action I: the effect of halothane on canine intracardiac impulse conduction during sinus rhythm.

The effect of halothane on intracardiac impulse conduction was assessed in dogs before and after pharmacologic vagotomy. Impulse conduction was measured by anesthetic-related changes in the A-H and H-V intervals of the His bundle electrogram. Prior to vagotomy, both "light" and "deep" halothane prolonged the A-H interval significantly. Maximal A-H interval prolongations corresponded to the maximal decrease in heart rate with either dose of anesthetic. Following vagotomy, the A-H prolongation produced by light halothane was abolished and the prolongation produced by the deep level greatly reduced. Neither dose of halothane had a measurable effect on the H-V interval before or after vagotomy. In one animal in which the effects of increasing rates of atrial pacing were measured without the addition of halothane, the A-H interval lengthened with no measurable change in the H-V interval. In two dogs in which the heart rate was held near pre-halothane levels by atrial pacing, the A-H interval was slightly prolonged and the H-V interval unchanged during the administration of deep halothane. These studies indicate that during sinus rhythm: (1) halothane prolongs A-V impulse conduction, (2) that this effect is correlated with a concomitant decrease in heart rate, and (3) that these effects are largely dependent upon intact vagal innervation of the heart. During atrial pacing, A-V conduction is prolonged by increased heart rate or by deep halothane when the heart rate is held constant. Thus, in addition to the known effects of halothane on pacemaker automaticity, concomitant changes in conduction may contribute to the antiarrhythmic action of this anesthetic.

Antiarrhythmic anesthetic action. II. The effect of methoxyflurane on ventricular automaticity.

During the course of surgical anesthesia, the majority of patients experience some arrhythmias, virtually all of which can be attributed to changes in cardiac pacemaker automaticity and/or alterations in cardiac conduction velocity. Therefore, a better understanding of these mechansims is of importance to anesthesiologists. Cardiac automaticity in the intact heart of dogs under methoxyflurane anesthesia was assessed by measuring changes in ventricular escape time (VET) and ventricular escape rate (VER). A slight shortening of VET was noted, while there was virtually no change from control in VER. Unexpectedly, however, a nonsinus supraventricular escape focus became prominent in many animals at a low anesthetic dose and in all animals at a higher anesthetic concentration. This effect was shown to be preventable by pretreatment with reserpine or a beta-blocking agent. It is concluded that methoxyflurane increases the automaticity of parts of the atrial conducting system, other than the sinus, either by a direct effect or by increasing the sensitivity to prevailing background adrenergic levels.

Anaphylaxis: etiology and guidelines for management.

The successful management of anaphylaxis requires a thorough understanding of this syndrome and the application of various therapeutic agents. Although the mechanisms responsible for human anaphylaxis are not fully known, sufficient data and clinical experience are available to guide the anesthesiologist faced with this medical emergency.